

Traverse Therapeutics Inc (TVTX) - Financial and Strategic SWOT Analysis Review

<https://marketpublishers.com/r/R5BE3E10783EN.html>

Date: September 2021

Pages: 50

Price: US\$ 125.00 (Single User License)

ID: R5BE3E10783EN

Abstracts

Traverse Therapeutics Inc (TVTX) - Financial and Strategic SWOT Analysis Review provides you an in-depth strategic SWOT analysis of the company's businesses and operations. The profile has been compiled by GlobalData to bring to you a clear and an unbiased view of the company's key strengths and weaknesses and the potential opportunities and threats. The profile helps you formulate strategies that augment your business by enabling you to understand your partners, customers and competitors better.

The profile contains critical company information including:

Business description – A detailed description of the company's operations and business divisions.

Corporate strategy – Analyst's summarization of the company's business strategy.

SWOT Analysis – A detailed analysis of the company's strengths, weakness, opportunities and threats.

Company history – Progression of key events associated with the company.

Major products and services – A list of major products, services and brands of the company.

Key competitors – A list of key competitors to the company.

Key employees – A list of the key executives of the company.

Executive biographies – A brief summary of the executives' employment history.

Key operational heads – A list of personnel heading key departments/functions.

Important locations and subsidiaries – A list and contact details of key locations and subsidiaries of the company.

Detailed financial ratios for the past five years – The latest financial ratios derived from the annual financial statements published by the company with 5 years history.

Interim ratios for the last five interim periods – The latest financial ratios derived from the quarterly/semi-annual financial statements published by the company for 5 interims history.

Highlights

Travere Therapeutics Inc (Travere Therapeutics), formerly Retrophin Inc, is a biopharmaceutical company that discovers, develops, acquires and markets drugs for the treatment of rare diseases. The company's products include thiola, chenodal and cholbam. It develops drugs for various catastrophic diseases. Travere Therapeutics pipeline products include sparsentan, used for the treatment of focal segmental glomerulosclerosis; RE-024, a product candidate to treat pantothenate kinase-associated neurodegeneration and RE-034, utilized for the treatment of severe rare diseases. The company markets its products through its distribution partners. It works in partnership with academia and independent researchers to support the development of novel solutions. The company operates in New York and Massachusetts, the US. Travere Therapeutics is headquartered in San Diego, California, the US.

Travere Therapeutics Inc Key Recent Developments

Jul 29,2021: Travere Therapeutics Reports Second Quarter 2021 Financial Results

Jul 22,2021: Travere Therapeutics to Report Second Quarter 2021 Financial Results

Jul 14,2021: Travere Therapeutics Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)

May 06,2021: Travers Therapeutics Reports First Quarter 2021 Financial Results
Apr 27,2021: Travers Therapeutics to Present at the BofA Securities 2021 Virtual Health Care Conference

Key benefits of buying this profile include:

You get detailed information about the company and its operations to identify potential customers and suppliers.

The profile analyzes the company's business structure, operations, major products and services, prospects, locations and subsidiaries, key executives and their biographies and key competitors.

Understand and respond to your competitors' business structure and strategies, and capitalize on their weaknesses. Stay up to date on the major developments affecting the company.

The company's core strengths and weaknesses and areas of development or decline are analyzed and presented in the profile objectively. Recent developments in the company covered in the profile help you track important events.

Equip yourself with information that enables you to sharpen your strategies and transform your operations profitably.

Opportunities that the company can explore and exploit are sized up and its growth potential assessed in the profile. Competitive and/or technological threats are highlighted.

Scout for potential investments and acquisition targets, with detailed insight into the companies' strategic, financial and operational performance.

Financial ratio presented for major public companies in the profile include the revenue trends, profitability, growth, margins and returns, liquidity and leverage, financial position and efficiency ratios.

Gain key insights into the company for academic or business research.

Key elements such as SWOT analysis, corporate strategy and financial ratios and charts are incorporated in the profile to assist your academic or business research needs.

Note: Some sections may be missing if data is unavailable for the company

Contents

SECTION 1 - ABOUT THE COMPANY

Travere Therapeutics Inc - Key Facts
Travere Therapeutics Inc - Key Employees
Travere Therapeutics Inc - Key Employee Biographies
Travere Therapeutics Inc - Major Products and Services
Travere Therapeutics Inc - History
Travere Therapeutics Inc - Company Statement
Travere Therapeutics Inc - Locations And Subsidiaries
Head Office
Other Locations & Subsidiaries

SECTION 2 – COMPANY ANALYSIS

Company Overview
Travere Therapeutics Inc - Business Description
Product Category: Bile Acid Products
Overview
Performance
Product Category: Tiopronin Products
Overview
Performance
R&D Overview
Travere Therapeutics Inc - Corporate Strategy
Travere Therapeutics Inc - SWOT Analysis
SWOT Analysis - Overview
Travere Therapeutics Inc - Strengths
Travere Therapeutics Inc - Weaknesses
Travere Therapeutics Inc - Opportunities
Travere Therapeutics Inc - Threats
Travere Therapeutics Inc - Key Competitors

SECTION 3 – COMPANY FINANCIAL RATIOS

Financial Ratios - Capital Market Ratios
Financial Ratios - Annual Ratios
Performance Chart

Financial Performance
Financial Ratios - Interim Ratios
Financial Ratios - Ratio Charts

SECTION 4 – COMPANY’S LIFESCIENCES FINANCIAL DEALS AND ALLIANCES

Travere Therapeutics Inc, Pharmaceuticals & Healthcare, Deals By Year, 2015 to YTD 2021

Travere Therapeutics Inc, Pharmaceuticals & Healthcare, Deals By Type, 2015 to YTD 2021

Travere Therapeutics Inc, Recent Deals Summary

SECTION 5 – COMPANY’S RECENT DEVELOPMENTS

Jul 29, 2021: Travere Therapeutics Reports Second Quarter 2021 Financial Results

Jul 22, 2021: Travere Therapeutics to Report Second Quarter 2021 Financial Results

May 06, 2021: Travere Therapeutics Reports First Quarter 2021 Financial Results

Apr 27, 2021: Travere Therapeutics to Present at the BofA Securities 2021 Virtual Health Care Conference

Apr 26, 2021: Travere Therapeutics to Report First Quarter 2021 Financial Results

Mar 01, 2021: Travere Therapeutics Reports Fourth Quarter and Full Year 2020 Financial Results

Feb 25, 2021: Travere Therapeutics recognizes Rare Disease Day 2021 and the importance of working together to innovate and address healthcare disparities in rare disease

Feb 22, 2021: Travere Therapeutics to Present at Upcoming Investor Conferences

Feb 16, 2021: Travere Therapeutics to Report Fourth Quarter and Full Year 2020 Financial Results

Jan 11, 2021: Travere Therapeutics provides corporate update and 2021 outlook

SECTION 6 – APPENDIX

Methodology
Ratio Definitions
About GlobalData
Contact Us
Disclaimer

List Of Tables

LIST OF TABLES

Travere Therapeutics Inc, Key Facts
Travere Therapeutics Inc, Key Employees
Travere Therapeutics Inc, Key Employee Biographies
Travere Therapeutics Inc, Major Products and Services
Travere Therapeutics Inc, History
Travere Therapeutics Inc, Subsidiaries
Travere Therapeutics Inc, Key Competitors
Travere Therapeutics Inc, Ratios based on current share price
Travere Therapeutics Inc, Annual Ratios
Travere Therapeutics Inc, Annual Ratios (Cont...1)
Travere Therapeutics Inc, Annual Ratios (Cont...2)
Travere Therapeutics Inc, Interim Ratios
Travere Therapeutics Inc, Pharmaceuticals & Healthcare, Deals By Year, 2015 to YTD 2021
Travere Therapeutics Inc, Pharmaceuticals & Healthcare, Deals By Type, 2015 to YTD 2021
Travere Therapeutics Inc, Recent Deals Summary
Currency Codes
Capital Market Ratios
Equity Ratios
Profitability Ratios
Cost Ratios
Liquidity Ratios
Leverage Ratios
Efficiency Ratios

List Of Figures

LIST OF FIGURES

Travere Therapeutics Inc, Performance Chart (2016 - 2020)

Travere Therapeutics Inc, Ratio Charts

Travere Therapeutics Inc, Pharmaceuticals & Healthcare, Deals By Year, 2015 to YTD 2021

Travere Therapeutics Inc, Pharmaceuticals & Healthcare, Deals by Type, 2015 to YTD 2021

I would like to order

Product name: Travers Therapeutics Inc (TVTX) - Financial and Strategic SWOT Analysis Review

Product link: <https://marketpublishers.com/r/R5BE3E10783EN.html>

Price: US\$ 125.00 (Single User License / Electronic Delivery)

If you want to order Corporate License or Hard Copy, please, contact our Customer Service:

info@marketpublishers.com

Payment

To pay by Credit Card (Visa, MasterCard, American Express, PayPal), please, click button on product page <https://marketpublishers.com/r/R5BE3E10783EN.html>

To pay by Wire Transfer, please, fill in your contact details in the form below:

First name:
Last name:
Email:
Company:
Address:
City:
Zip code:
Country:
Tel:
Fax:
Your message:

****All fields are required**

Customer signature _____

Please, note that by ordering from marketpublishers.com you are agreeing to our Terms & Conditions at <https://marketpublishers.com/docs/terms.html>

To place an order via fax simply print this form, fill in the information below and fax the completed form to +44 20 7900 3970